A full 14 years after founding CRO Clinipace, its longstanding CEO and president Jeff Williams is to step down.
The chief’s role will be handed over to Jason Monteleone, who founded Pivotal Financial Consulting, a consulting firm with a focus on CROs, while Williams moves into an “expanded advisory role” within the board, according to a statement.
“I am extremely proud of what we have built at Clinipace, but the time has come for me to replace myself and it is my pleasure to welcome Jason Monteleone as CEO,” said Williams.
“After seeing him in action as a consultant to Clinipace over the last several months, I am confident he will build successfully on our company’s 14-year history and lead us into its next phase of growth.”
Williams has over the past three years been an acquisitive chief, buying up European CRO Accovion as well as Hong Kong CRO Choice Pharma, Paragon Biomedical, PFC Pharma, Regulus Pharmaceutical and Worldwide Clinical Research.
It now has more than 800 staffers and has completed more than 1,500 clinical trials.
Monteleone added: “I am honored to join Clinipace on the heels of the remarkable accomplishments that Jeff and his organization have achieved. I am confident that the strong foundation he built, and the talented team here, will serve us well as we continue our quest to make Clinipace the leading mid-market CRO.”
By Ben Adams
Source: Fierce Biotech
The new company will have four complementary businesses: Perfumery & Beauty, Food & Beverage/Taste & Beyond, Health, Nutrition & Care and Animal Nutrition & Health, each with strong market positions and expertise to address emerging consumer trends. The businesses will also prioritize environmental sustainability, health and well-being.
Merck (MSD) has signed a definitive agreement for the acquisition of all outstanding shares of Imago BioSciences for a total equity price of nearly $1.35bn. A clinical-stage biopharmaceutical firm, Imago focuses on the development of new therapies to treat myeloproliferative neoplasms (MPNs) and other bone marrow ailments.
Danish pharma Novo Nordisk has announced plans to invest 5.4 billion Danish kroner to expand its existing facilities in Bagsværd. The project will establish extra R&D capacity for manufacturing APIs to supply the company’s global clinical trials for oral and injectable products. The expansion is expected to be finished in 2024, creating about 160 new jobs.